(Q86168658)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25466241%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25466241%20AND%20SRC:MED&resulttype=core&format=json

chronic renal insufficiency

24 February 2020

main subject

1 reference

Murray Epstein

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25466241%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

1 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25466241%20AND%20SRC:MED&resulttype=core&format=json

The Lancet: Diabetes & Endocrinology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25466241%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25466241%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25466241%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

925-927

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25466241%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970216-5

7 January 2021

Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970216-5

7 January 2021

Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970216-5

7 January 2021

Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970216-5

7 January 2021

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970216-5

7 January 2021

Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970216-5

7 January 2021

Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970216-5

7 January 2021

Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970216-5

7 January 2021

10.1016/S2213-8587(14)70216-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25466241%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference